Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-08T01:33:33.593Z Has data issue: false hasContentIssue false

Growing healthy muscles to optimise metabolic health into adult life

Published online by Cambridge University Press:  09 October 2014

S. A. Bayol*
Affiliation:
School of Exercise and Nutrition Sciences, Centre for Physical Activity and Nutrition Research, Faculty of Health, Deakin University, Melbourne, VIC, Australia
C. R. Bruce
Affiliation:
School of Exercise and Nutrition Sciences, Centre for Physical Activity and Nutrition Research, Faculty of Health, Deakin University, Melbourne, VIC, Australia
G. D. Wadley
Affiliation:
School of Exercise and Nutrition Sciences, Centre for Physical Activity and Nutrition Research, Faculty of Health, Deakin University, Melbourne, VIC, Australia
*
*Address for correspondence: S. A. M. Bayol, School of Exercise and Nutrition Sciences, Centre for Physical Activity and Nutrition Research, Faculty of Health, Deakin University, Melbourne, VIC 3125, Australia. (Email stephanie.bayol@deakin.edu.au)
Rights & Permissions [Opens in a new window]

Abstract

The importance of skeletal muscle for metabolic health and obesity prevention is gradually gaining recognition. As a result, interventions are being developed to increase or maintain muscle mass and metabolic function in adult and elderly populations. These interventions include exercise, hormonal and nutritional therapies. Nonetheless, growing evidence suggests that maternal malnutrition and obesity during pregnancy and lactation impede skeletal muscle development and growth in the offspring, with long-term functional consequences lasting into adult life. Here we review the role of skeletal muscle in health and obesity, providing an insight into how this tissue develops and discuss evidence that maternal obesity affects its development, growth and function into adult life. Such evidence warrants the need to develop early life interventions to optimise skeletal muscle development and growth in the offspring and thereby maximise metabolic health into adult life.

Information

Type
Review
Copyright
© Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2014 
Figure 0

Table 1 Correlation between skeletal muscle fitness and metabolic health in children and adolescents

Figure 1

Fig. 1 Contribution of skeletal muscle in glucose disposal in the post-absorptive (fasted) and post-prandial (fed) states. (a) Post-absorptive glucose metabolism. The liver and kidneys contribute ∼80% and 20% of glucose output, respectively. Most glucose is then removed from the circulation by non-insulin-sensitive tissues such as the brain (50%), renal medulla (10%), blood cells (10%) and the splanchnic bed (10%). The remaining 20–25% are taken up by skeletal muscles and adipose tissue. (b) Post-prandial glucose metabolism. Following an oral glucose load of 100 g, ∼30 g are taken up by the liver and 70 g are released into the circulation. Of these 70 g, 27 g (40%) are taken up by skeletal muscle, 5 g (7%) by adipose tissue, 15 g (20%) return to the liver and the remaining 23 g (33%) are taken up by the kidneys, skin and blood cells. Figure adapted from Shrayyef and Gerich.97

Figure 2

Fig. 2 Model of skeletal muscle insulin-resistance in obesity. Excess plasma free fatty acid (FFA) leads to the intramuscular accumulation of long-chain fatty acid (LCFA)-Acyl CoAs. Because of low energy demand, LCFA-Acyl CoAs are incompletely oxidised by mitochondria thus form large lipid droplets. Lipolysis of these droplets generates lipotoxic precursors such as diacyglycerol (DAG) and ceramide. Both LCFA-Acyl-CoA and DAG activate protein kinase C (PKC), which stimulates serine phosphorylation. This decreases the association between insulin receptor substrate 1 and phosphatidylinosytol (PI3K). Ceramide impair insulin signalling via decreased Akt/protein kinase B (PKB) phosphorylation. The resulting downregulation of insulin signalling prevents the translocation of glucose transporter (GLUT) 4 to the plasma membrane and glucose uptake into skeletal muscle (adapted from Shaw et al.,102 Consitt et al.103 and Coen and Goodpaster104).

Figure 3

Fig. 3 Skeletal muscle development. During early embryogenesis, skeletal muscle precursor cells delaminate from the somites located on either side of the neural tube and migrate into the limb buds and trunk (a). Muscle fibre formation occurs in waves and ends before birth or shortly thereafter depending on species. Primary myofibres form first and act as scaffolding for secondary myofibres (b). After birth, myofibres continue to grow by hypertrophy, which initially involves the activation of satellite cells located under the basal lamina (c). Figure adapted from Partridge121 and Maltin et al.5

Figure 4

Fig. 4 Mechanisms of postnatal skeletal muscle growth. (a) Satellite cells are quiescent muscle precursors located under the basal lamina. Upon activation, they proliferate. Some daughter cells return to quiescence to replenish the satellite cell pool, whereas others fuse with the adjacent muscle fibre and donate their nuclei to contribute to protein synthesis and thereby skeletal muscle fibre growth. Each stage of satellite cell differentiation is regulated by factors involved in myogenesis. RBP-J and miR-489 are required to maintain satellite cells in a quiescent state while Spry1 and Notch-3 regulate their return to quiescence from a proliferating state. Myf5 is involved in satellite cell proliferation while MyoD and myogenin regulate their differentiation and expression of functional contractile proteins such as MyHCs. (b) Various signalling pathways are believed to converge around Akt/mTOR to regulate skeletal muscle hypertrophy through transcriptional regulation (arrow linking mTOR to a myonucleus). The two major regulatory pathways are IGF-1 acting through PI3K and follistatin acting through myostatin inhibition (heavy dotted lines). Additional pathways include SRF, PA and nNOS. miR-489, mouse micro RNA-489; Myf5, myogenic factor 5; myHC, myosin heavy chain; MyoD, myogenic differentiation; Notch-3, neurogenic locus notch homologue protein 3; Pax7, paired box protein 7; RBP-J, recombination signal binding protein for immunoglobulin kappa J region; Spry1, protein sprouty homologue 1. Figure adapted from Brack and Rando.122; ACVRI/II, activin receptor I/II; akt, serine/threonine protein kinase; Fzd7, frizzled family receptor 7; IGF1, insulin-like growth factor-1; IGF1R, insulin-like growth factor-1 receptor; IL, interleukin; mTOR, mechanistic target of rapamycin (serine/threonine kinase); new mn, newly fused myonucleus; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; PA, phosphatidic acid; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; SC, satellite cell; SRF, serum response factor; SSC, satellite stem cell; TRPV1, transient receptor potential cation channel subfamily V member 1; wnt7a, wingless-type MMTV integration site family, member 7A. Figure adapted from Schiaffino et al.120

Figure 5

Fig. 5 Maternal obesity may affect stem cell specification in the developing offspring. Skeletal muscle and adipose tissues (white and brown) derive from a common mesenchymal precursor. Specification to each lineage is a competitive process regulated by a number of regulatory factors shown in blue (adapted from Park et al.).166 Growing evidence suggests that maternal diet-induced obesity may promote a mesenchymal cell differentiation-shift down the adipogenic lineage at the expense of myogenesis in the developing offspring. As a result, the skeletal muscle compartment is compromised and contractile and metabolic functions are altered. CD24, cluster of differentiation 24; C/EBPα, CCAAT-enhancer-binding proteins α; MyoD, myogenic differentiation; PGC-1, peroxisome proliferative-activated receptor gamma coactivator 1; PPARγ, peroxisome proliferator-activated receptor γ; PRDM16, PR domain containing 16; RIP140, receptor-interacting protein 140; SRC1/2, Proto-oncogene non-receptor tyrosine kinase.